Company / Revenue
Vanda Pharmaceuticals Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$192.6M
FY2025
5-year range
$192.6M / $268.7M
FY2021-FY2025
Trend
-24.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $269M to $193M over the past 2 years.
Based on SEC 10-K filings.
$193M in FY2025 with a 5-year CAGR of -0.0%.
Declined from $269M to $193M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- -0.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -0.0%, indicating a declining trend.
- In FY2025, revenue decreased 24.3% year-over-year.
- Peak revenue was recorded in FY2023.
- Lowest revenue in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $192.6M | -24.3% |
| FY2024 | $254.4M | -5.3% |
| FY2023 | $268.7M | +8.3% |
| FY2022 | $248.2M | +9.2% |
| FY2021 | $227.2M | +17.6% |
| FY2020 | $193.1M | +17.0% |
| FY2019 | $165.1M | +13.1% |
| FY2018 | $146.0M | +32.8% |
| FY2017 | $109.9M | +119.2% |
| FY2016 | $50.2M | +48.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026